It’s worth noting that comparable results have been observed in models of breast and pancreatic cancer, where the combination of CD73 targeting with RT, further augmented with CTLA-4 and PD-1 immune checkpoint inhibitors, respectively, demonstrated enhanced antitumor activity [8, 20]. This evidence concerns the gene CTLA4 and pancreatic neoplasm.